Keytruda (pembrolizumab) 100 mg/4 mL concentrate for solution for infusion — original (MSD, Ireland) Late-stage melanoma Drug delivery from Europe and beyond, within 4-5 days, storage conditions observed, payment upon receipt. Order by calling +380996042415, Viber, WhatsApp

Indications for Use

Keytruda is indicated for use in patients with late-stage melanoma that has metastasized; surgery to remove the tumor is not possible for a number of reasons; and therapy with other medications and methods has proven ineffective.

Method of Administration

Treatment with Keytruda should be initiated and administered under the supervision of qualified and experienced oncologists.
Patients should be selected for treatment of NSCLC with Keytruda based on positive PD-L1 expression.
The drug is administered intravenously through a special line at a dosage of 2 mg per kilogram of the patient's weight, and in particularly severe cases, 10 mg should be administered.
However, it should be remembered that the dosage should be determined only by a doctor. The drug should be used every 3 weeks.